Philip Beachy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Philip beachy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Philip Beachy Today - Breaking & Trending Today

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) have been given a consensus rating of “Hold” by the twenty-three research firms that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and five have issued a buy recommendation on the […] ....

Alexander Rives , Philip Beachy , Michael Rudnicki , Stifel Nicolaus , David Scadden , Scott Wolchko , Piper Sandler , Rudolf Jaenisch , Leonard Zon , Ef Hutton Acquisition Co , Fate Therapeutics Inc , Advisor Group , Envestnet Asset Management Inc , Securities Exchange Commission , Redmile Group Llc , Fate Therapeutics Company Profile , Raymond James Associates , Cantor Fitzgerald , Hightower Advisors , Financial Services Group Inc , Fate Therapeutics , Get Rating , Director Redmile Group , Exchange Commission , Asset Management , Tower Advisors ,

Essential Properties Realty Trust, Inc. (NYSE:EPRT) Receives $25.93 Consensus PT from Analysts

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its target price lowered by Stifel Nicolaus from $5.30 to $5.00 in a research report sent to investors on Thursday, The Fly reports. Several other analysts also recently weighed in on the stock. HC Wainwright downgraded shares of Fate Therapeutics from a buy rating to a neutral rating […] ....

Rudolf Jaenisch , Philip Beachy , Stifel Nicolaus , Michael Rudnicki , Leonard Zon , Alexander Rives , Scott Wolchko , David Scadden , Blackrock Inc , Pricet Rowe Associates Inc , Vanguard Group Inc , Wells Fargo Company , Fate Therapeutics Inc , Redmile Group Llc , Fate Therapeutics , Get Rating , Director Redmile Group , Street Corp , Capital World Investors , World Investors , Sheng Ding , Fate Therapeutics Daily , Nasdaq Fate , Lower Price Target ,

Cantor Fitzgerald Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $5.00

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its target price lowered by Cantor Fitzgerald from $8.00 to $5.00 in a report published on Thursday, The Fly reports. FATE has been the topic of a number of other reports. Morgan Stanley reduced their price objective on shares of Fate Therapeutics from $35.00 to $8.00 and set […] ....

United States , Philip Beachy , Michael Rudnicki , Alexander Rives , Scott Wolchko , David Scadden , Leonard Zon , Rudolf Jaenisch , Morgan Stanley , Cantor Fitzgerald , Blackrock Inc , Fate Therapeutics Inc , Redmile Group Llc , Vanguard Group Inc , Securities Exchange Commission , Pricet Rowe Associates Inc , Fate Therapeutics , Get Rating , Truist Financial , Therapeutics Stock Down , Director Redmile Group , Exchange Commission , Street Corp , Capital World Investors , World Investors , Sheng Ding ,

Fate Therapeutics (NASDAQ:FATE) Given New $5.00 Price Target at Stifel Nicolaus

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price objective cut by Stifel Nicolaus from $5.30 to $5.00 in a report issued on Thursday morning, The Fly reports. Other analysts also recently issued reports about the stock. HC Wainwright downgraded shares of Fate Therapeutics from a buy rating to a neutral rating and reduced their […] ....

United States , David Scadden , Scott Wolchko , Leonard Zon , Stifel Nicolaus , Michael Rudnicki , Alexander Rives , Rudolf Jaenisch , Philip Beachy , Managers Group , Fate Therapeutics Company Profile , Fate Therapeutics Inc , Redmile Group Llc , Coppell Advisory Solutions Corp , Ci Investments Inc , Nisa Investment Advisors , Fate Therapeutics , Get Rating , Therapeutics Stock Down , Director Redmile Group , Investment Advisors , Coppell Advisory Solutions , Sheng Ding , Fate Therapeutics Daily , Nasdaq Fate , Lower Price Target ,

Fate Therapeutics (NASDAQ:FATE) Price Target Cut to $5.00 by Analysts at Cantor Fitzgerald

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price target trimmed by Cantor Fitzgerald from $8.00 to $5.00 in a research report report published on Thursday, The Fly reports. Several other brokerages have also issued reports on FATE. Morgan Stanley cut their price target on Fate Therapeutics from $35.00 to $8.00 and set an equal […] ....

Philip Beachy , Leonard Zon , Rudolf Jaenisch , David Scadden , Alexander Rives , Scott Wolchko , Michael Rudnicki , Morgan Stanley , Nisa Investment Advisors , Coppell Advisory Solutions Corp , Ci Investments Inc , Fate Therapeutics Inc , Cantor Fitzgerald , Managers Group , Redmile Group Llc , Fate Therapeutics , Get Rating , Director Redmile Group , Investment Advisors , Coppell Advisory Solutions , Sheng Ding , Fate Therapeutics Daily , Nasdaq Fate , Lower Price Target ,